Latest Production Development News

Mesoblast Limited’s Ryoncil® posted US$36 million in Q4 revenue, driving a full-year total of US$115 million, exceeding initial forecasts. The FDA-approved stem cell therapy for pediatric graft-versus-host disease shows robust uptake across US pediatric centres.

8common Limited posted positive EBITDA and net profit before tax in Q4 FY26, secured a major multi-year contract with the Australian Taxation Office, and fully repaid its loan facility.

ClearVue Technologies has earned three international certifications for its Gen 3 Vision Glass, confirming its photovoltaic performance, safety, and durability across multiple product variants.

Spenda Limited has completed the retail tranche of its $8.545 million entitlement offer, raising $1.15 million at $0.004 per share, with major shareholder Capricorn Society increasing its holding to nearly 20%.

BCAL Diagnostics has acquired a 10.2% stake in Genetic Signatures for $1.39 million, aiming to merge early cancer detection with infectious disease diagnostics and expand its international footprint.

HALO Technologies launches a convertible notes offer aiming to raise up to A$6.75 million, backing platform upgrades and expansion across Asia-Pacific and adviser networks.

Spenda Limited's SPXOB securities have been suspended from trading by the ASX due to non-compliance with listing requirements. The suspension affects only this security class, leaving other Spenda securities unaffected.

Echo IQ has locked in a pivotal exclusive data licensing deal with Advara HeartCare, gaining access to as many as one million de-identified echocardiography studies, a move set to turbocharge its cardiovascular AI development.

Echo IQ has raised approximately A$110 million through a heavily supported institutional placement to fund its US commercial rollout and speed up development of its AI-driven cardiovascular diagnostics.

Chimeric Therapeutics has appointed Hawkesbury Partners to lead a strategic review aimed at exploring options to enhance shareholder value, reflecting concerns that its market cap undervalues its clinical assets and infrastructure.

CONNEQT Health Limited is offering eligible shareholders a share purchase plan to raise up to $0.5 million at a 24.3% discount, aiming to fund its next growth phase in vascular health technology.

Sparc Technologies has unveiled SparcESTM, a graphene additive range designed for electrostatic and conductive coatings, aiming to disrupt a $1.65 billion market driven by data centres, semiconductors, and EV battery manufacturing.